Boston Scientific slashes 2026 guidance

Leave a Comment / By /

CEO Mike Mahoney told investors that the lowered forecast reflects challenges for several businesses, including electrophysiology and Watchman.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top